Technical Analysis for WVE - WAVE Life Sciences Ltd.

Grade Last Price % Change Price Change
grade C 41.95 -4.66% -2.05
WVE closed down 4.66 percent on Friday, March 22, 2019, on 45 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical WVE trend table...

Date Alert Name Type % Chg
Mar 22 20 DMA Resistance Bearish 0.00%
Mar 22 Fell Below 200 DMA Bearish 0.00%
Mar 22 New Downtrend Bearish 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 22 Down 4 Days in a Row Weakness 0.00%
Mar 21 Fell Below 20 DMA Bearish -4.66%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -4.66%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.66%
Mar 21 Doji - Bullish? Reversal -4.66%

Older signals for WVE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington's disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In Huntington's disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company was founded in 2012 and is based in Singapore.
Rare Diseases Medical Genetics Inflammatory Bowel Disease Huntington's Disease Muscular Dystrophy Duchenne Muscular Dystrophy Genetic Genealogy Genodermatoses Cytoskeleton Dystrophin Ibd SNP
Is WVE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 56.0
52 Week Low 32.25
Average Volume 411,768
200-Day Moving Average 43.47
50-Day Moving Average 40.6208
20-Day Moving Average 44.303
10-Day Moving Average 45.636
Average True Range 1.9444
ADX 29.14
+DI 21.494
-DI 23.521
Chandelier Exit (Long, 3 ATRs ) 42.8068
Chandelier Exit (Short, 3 ATRs ) 42.2132
Upper Bollinger Band 49.3429
Lower Bollinger Band 39.2631
Percent B (%b) 0.27
BandWidth 22.751958
MACD Line 1.2275
MACD Signal Line 1.7013
MACD Histogram -0.4738
Fundamentals Value
Market Cap 1.16 Billion
Num Shares 27.8 Million
EPS -3.35
Price-to-Earnings (P/E) Ratio -12.52
Price-to-Sales 250.07
Price-to-Book 3.20
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 46.72
Resistance 3 (R3) 47.14 45.98 45.93
Resistance 2 (R2) 45.98 44.76 45.77 45.66
Resistance 1 (R1) 43.96 44.01 43.38 43.54 45.39
Pivot Point 42.80 42.80 42.51 42.59 42.80
Support 1 (S1) 40.78 41.58 40.20 40.36 38.51
Support 2 (S2) 39.62 40.83 39.41 38.24
Support 3 (S3) 37.60 39.62 37.98
Support 4 (S4) 37.18